The agency also cleared Roche's assay for diagnosing thyroid or pituitary disorders, as well as tests from Beckman Coulter, Immunostics, and BioMérieux.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The company said it ultimately plans to use the liquidity from the credit facility to fund a portion of its pending $4 billion acquisition of Cepheid.
The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
Phenomenex, a privately held manufacturer of consumables for the separation sciences, will operate as a standalone business and will retain its brand.